The efficacy of voriconazole in the treatment of 192 fungal central nervous system infections: a retrospective analysis

Purpose The efficacy of voriconazole against fungal central nervous system (CNS) infections was examined retrospectively. Methods Voriconazole-treated patients with proven (137) or probable (55) CNS infections were identified in the voriconazole database (114) and the literature (78). Investigator-d...

Full description

Saved in:
Bibliographic Details
Published in:Infection 2011-06, Vol.39 (3), p.201-210
Main Authors: Schwartz, S., Reisman, A., Troke, P. F.
Format: Article
Language:English
Subjects:
Adolescent
Adult
Age
Aged
Aged, 80 and over
Antifungal Agents - therapeutic use
Aspergillosis - drug therapy
Aspergillosis - microbiology
Aspergillus
Aspergillus - pathogenicity
Biological and medical sciences
Central nervous system
Central Nervous System Fungal Infections - drug therapy
Central Nervous System Fungal Infections - microbiology
Central Nervous System Fungal Infections - pathology
Child
Child, Preschool
Clinical and Epidemiological Study
Family Medicine
Female
General Practice
Humans
Immunosuppression
Infant
Infectious Diseases
Internal Medicine
Male
Malignancy
Medical sciences
Medicine
Medicine & Public Health
Middle Aged
Miscellaneous
Neurosurgery
Pediatrics
Public health. Hygiene
Public health. Hygiene-occupational medicine
Pyrimidines - therapeutic use
Retrospective Studies
Scedosporium
Scedosporium - pathogenicity
stem cell transplantation
Stem cells
Surgery
Survival
Transplantation
Treatment Outcome
Triazoles - therapeutic use
Voriconazole
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose The efficacy of voriconazole against fungal central nervous system (CNS) infections was examined retrospectively. Methods Voriconazole-treated patients with proven (137) or probable (55) CNS infections were identified in the voriconazole database (114) and the literature (78). Investigator-determined success was a complete or partial response. Survival was calculated from the start of voriconazole therapy. Results The patients’ age range was
ISSN:0300-8126
1439-0973
DOI:10.1007/s15010-011-0108-6